| Abstract: |
In the last 30 years, a multitude of treatment regimens for adult acute lymphocytic leukemia (ALL) has been developed. Essentially, all of these regimens use an induction therapy vincristine, prednisone, and an anthracycline intensified with L-asparaginase or cyclophosphamide. Though such regimens induce most patients to enter a remission, relapse is frequent, and most adult patients ultimately die of their disease. The author postulated that further refinements in this approach to induction therapy were unlikely to markedly improve treatments results in this disease. Therefore, the author is studying a new intensive strategy using cytarabine with a single very high dose of mitoxantrone (without vincristine or prednisone) as induction therapy for adult patients with ALL. |
| Keywords: |
adolescent; adult; cancer survival; controlled study; treatment outcome; aged; middle aged; survival analysis; major clinical study; prednisone; clinical trial; neutropenia; review; cancer recurrence; doxorubicin; cancer combination chemotherapy; cytarabine; methotrexate; prospective studies; controlled clinical trial; phase 2 clinical trial; bone marrow suppression; etoposide; antineoplastic combined chemotherapy protocols; cyclophosphamide; vincristine; carmustine; cancer regression; randomized controlled trials; multicenter study; mitoxantrone; daunorubicin; dactinomycin; remission induction; asparaginase; phase 3 clinical trial; acute lymphocytic leukemia; recombinant granulocyte colony stimulating factor; anthracycline; leukocytosis; drug induced disease; philadelphia 1 chromosome; mercaptopurine; filgrastim; lymphoblastoma; 6-mercaptopurine; multicenter studies; clinical trials, phase ii; clinical trials, phase iii; leukemia, lymphocytic, acute; lymphoma, lymphoblastic; humans; human; male; female; priority journal; controlled clinical trials
|
